On September 23, 2024, the U.S. Food and Drug Administration (FDA) approved bimekizumab-bkzx (BIMZELX®, UCB) for the treatment of active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and active ankylosing spondylitis (AS).1 This makes bimekizumab-bkzx the first treatment available in the USA that selectively inhibits both interleukin 17A (IL-17A) […]
New research presented at UEG Week 2024 has introduced a strategy that could considerably reduce the need for insulin therapy in patients with type 2 diabetes (T2D).¹ The study investigated a novel approach combining ReCET (Re-Cellularization via Electroporation Therapy) with the GLP-1 RA, semaglutide. Remarkably, 86% of participants enrolled in the study were able to […]
Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.
Join us as we unveil the content that made the greatest impact in 2024.
From insightful Q&As and news articles to engaging podcasts, conference highlights, and medical education resources, this year has been filled with valuable content designed to support your daily practice and, ultimately, enhance patient care.
Education, Conference Coverage and Articles
Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.
There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an ...
International experts from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) have recently partnered to produce the much-anticipated classification criteria for antiphospholipid syndrome (APS), which were published in Arthritis & Rheumatology in August 2023.1 ...
Chronic back pain (CBP), defined as back pain lasting for 3 months or more, is the most common pain condition globally.1 Greater healthcare utilization, productivity limitations and poor quality of life have immediate and long-term impacts on patients and the healthcare ...
Watch leading experts discuss updates in the treatment of systemic lupus erythematosus (SLE), lupus nephritis (LN) and Sjögren’s disease, based on data presented at EULAR 2024.
Watch Drs Ronald Vender, Richard Warren and Xenofon Baraliakos discuss UCB’s contributions to the treatment of immunological disease.
Share your knowledge, influence clinical practices and enhance patient care in Immunology today!
This corrects the article: “Gheriani GA, Tuetken R and Lenert P. Lane–Hamilton Syndrome: A Vasculitis Mimic Presenting with Diffuse Alveolar Haemorrhage and Positive ANCA Testing. touchREVIEWS in RMD. 2024;3(1):37–42” The patient consent statement was added incorrectly due to an editorial ...
It is increasingly recognized that autoimmune rheumatic diseases (ARDs) can affect people of any age, starting from early childhood and continuing until later in life. Furthermore, in recent decades, it has become apparent that Sjögren disease (SjD), commonly diagnosed ...
This editorial outlines a clinical approach to patients with periodic inflammation of unknown origin despite initial rational and targeted investigation. The focus of the editorial is on the recognition and diagnosis of systemic autoinflammatory diseases (SAIDs). Although rare, SAIDs are ...
The global burden of disease is heavily impacted by the increased prevalence of chronic inflammatory rheumatic diseases (CIRDs [rheumatoid arthritis (RA), spondyloarthritis (SpA), connective tissue diseases (CTDs) crystal arthropathies and polyarticular osteoarthritis (OA)]), which are prevalent chronic non-communicable diseases associated ...
Systemic lupus erythematosus (SLE) predominantly affects females and is characterized by multisystem involvement.1,2 Despite advancements in therapeutics, patients with SLE still experience poor health-related quality of life (HRQoL).3 Systemic sclerosis (SSc) is characterized by vasculopathy and fibrosis of the skin ...
Diffuse alveolar haemorrhage (DAH) is associated with high morbidity and mortality. The causes of DAH are diverse, and include rheumatologic conditions such as granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), Systemic lupus erythematosus (SLE) and Goodpasture’s syndrome (Table 1). Rheumatologists ...
Although biological disease-modifying antirheumatic drugs (bDMARDs) are significantly cheaper now that biosimilar agents are available, they still represent a significant cost to health services worldwide, particularly since their prescription has only increased since the thresholds for commencing this treatment have ...
Systemic lupus erythematosus (SLE) is a multisystem, autoimmune disorder affecting skin, joints, kidneys, the heart, lungs, the brain and blood cells, and is characterized by heterogeneous presentations and severity. It is more common in females than males, with a ratio ...
Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints but may be accompanied by systemic and extra-articular manifestations.1,2 Patients with RA are associated with a higher mortality rate compared with the general population and with increased ...
Biologics are medications derived from biological sources used to treat several immune-mediated inflammatory diseases. These medications interfere with autoimmune processes by inhibiting specific molecular or cellular targets. They are highly effective medications, mostly used in cases of moderate-to-severe disease activity. ...
Watch highlights of three ADVENT symposia presented at EADV 2023
Introducing the Editorial Board of touchREVIEWS in Immunology, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.
Rheumatoid Arthritis
Head of Clinical Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
Peter C Taylor holds the Norman Collison chair of musculoskeletal sciences at the University of Oxford and is a Fellow of St. Peter’s College. He is Head of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. He studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge and his first degree was in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for research on pathogenesis of arthritis. Professor Taylor has specialist clinical interests in inflammatory arthritis. He has over 25 years’ experience in clinical trial design in studies of biologic and small molecular therapies in rheumatoid arthritis and ankylosing spondylitis. In experimental medicine studies, Professor Taylor employs targeted therapies as probes of pathogenesis to investigate the in vivo biology of the target in the pathobiology of the disease phenotype under investigation.
Rheumatoid Arthritis
Centre for Rheumatic Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UK
Elena Nikiphorou, MBBS/BSc, FRCP, MD(Res), PGCME, FHEA Dr Elena Nikiphorou is a Consultant Rheumatologist and an Honorary Senior Lecturer at Kings College London. She completed her MBBS at University College London, also obtaining a first-class honours for her Intercalated BSc in physiology, a British Pharmacological Society Award and a Wellcome Trust Vacation Scholarship for her BSc Research. She has been the recipient of multiple awards, bursaries and competitive roles, including the Richard Kovacs prize by the Royal Society of Medicine in 2014, which supported a fellowship in Chicago and the Doris Hillier Award by the British Medical Association in 2018, to support her work on multimorbidity in rheumatoid arthritis and the development of management algorithms according to individual need. with a clinical/academic interest in inflammatory arthritis, rheumatoid arthritis and spondyloarthritis. She has expertise in all aspects of general rheumatology, including connective tissue and metabolic bone disease; crystal (e.g., gout) and reactive arthritis.
Rheumatoid Arthritis
Senior Rheumatologist at Cochin Hospital and Professor at the University of Paris, Rheumatology Department, Paris, France
Jérôme Avouac is a senior rheumatologist at Cochin Hospital and Professor at the University of Paris. He is responsible for a sector of day hospitalisation in the Rheumatology department, whose recruitment is mainly composed of patients with chronic inflammatory rheumatic disorders. He established a standardized systematic follow-up of joint involvement and systemic complications of rheumatoid arthritis and other inflammatory rheumatic diseases. Based on this standardized follow-up and clinical studies, he is developing medical approaches of personalized medicine for rheumatoid arthritis. Within the “Pathogenesis And Innovative Therapies In Chronic Fibro-Inflammatory Diseases” team at the Cochin Institute (INSERM U1016 UMR8104), Prof. Avouac leads innovative projects regarding the vascular aspects of inflammatory rheumatic disorders, especially rheumatoid arthritis. He also participates in the preclinical evaluation of anti-fibrotic treatments thanks to a platform of complementary animal models with dermal, pulmonary and vascular fibrosis.
Systemic Lupus Erythematosus
Rheumatologist, Division of Rheumatology, Northwell Health, and Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
Dr Richard Furie is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease. He also directs the Hospital’s systemic lupus erythematosus (SLE) and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE. Regarded as one of the senior rheumatologists in the New York metropolitan area, he has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. He has served on many committees of the American College of Rheumatology and was named a Master of the College in 2018.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.